drugset / Trial / NCT05254561
Triple Antigen vs Monoantigen Immunotherapy for Warts
RandomizedParallel-groupDouble-blindTreatment
Summary
Warts can be resistant to treatment or return despite the use of many therapeutic modalities. Combining immunotherapy might contribute to better response rates, particularly in recalcitrant warts, which is a real therapeutic challenge. The purpose of this study was to assess the effectiveness and safety of a triple intralesional immunotherapy combination composed of PPD, Candida antigen and MMR versus either agent alone in the management of multiple recalcitrant warts.
Timeline
- Start
- 2020-11-20
- Primary completion
- 2021-06-20
- Completion
- 2021-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Candida antigen | Vaccine | — | Other |
| Comparator | Measles, Mumps and Rubella vaccine | Vaccine | — | Other |
| Comparator | tuberculin | Diagnostic / imaging agent | — | Other |
Indications
No indication recorded.